

Hypothesis

Not peer-reviewed version

Combined Glucose and Thiamine Treatment for Sepsis

[Patrick Bradley](#)*

Posted Date: 15 January 2026

doi: 10.20944/preprints202601.1109.v1

Keywords: sepsis; mitochondria; adenosine triphosphate; ATP; pyruvate dehydrogenase complex; PDHC; thiamine; glycolysis; glucose; insulin; lipopolysaccharides; LPS; oxidative phosphorylation; OXPHOS; pyruvate dehydrogenase kinase; PDK; lactate



Preprints.org is a free multidisciplinary platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This open access article is published under a [Creative Commons CC BY 4.0 license](#), which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Hypothesis

Combined Glucose and Thiamine Treatment for Sepsis

Patrick Bradley

Independent Researcher, Wollongong, NSW 2500, Australia; pjbradley44@gmail.com; ORCID 0000-0003-4528-912X

Abstract

The current consensus model of sepsis is that it is a dysregulated host response to infection associated with severe organ dysfunction and failure. In 2023 the author proposed a new model of sepsis in that it was a physiological response and defence to infection that failed or became “dysregulated” particularly if the infection was overwhelming or there was a deficiency of thiamine and/or intracellular glucose to provide ongoing fuel for the immune response and/or mitochondrial production of adenosine triphosphate (ATP). This new model proposed that during sepsis, the immune system received priority access to available glucose, prompting insulin resistance that minimised glucose utilisation by less essential tissues. Concurrently, mitochondrial ATP production via oxidative phosphorylation (OXPHOS) was deprioritised, with the immune system relying on anaerobic glycolysis for ATP generation. This suppression of OXPHOS was only a temporary measure; mitochondrial ATP production had to be resumed for complete recovery. Its persistent suppression could culminate in critical ATP deficits and cell death. This paper reviews the consensus model of sepsis and evidence for the new model. It also reviews glucose, thiamine and insulin metabolism in sepsis and concludes that administering high-dose insulin alongside mild hyperglycaemia and intravenous thiamine—a pyruvate dehydrogenase kinase (PDK) inhibitor—may help restore physiological mitochondrial ATP production when administered during a crucial window in the sepsis process, potentially improving survival outcomes. The thrust of this new model may have been validated by a recent experiment on sepsis in mice that found superior survival following treatment with combined glucose and thiamine compared to antibiotics.

Keywords: sepsis; mitochondria; adenosine triphosphate; ATP; pyruvate dehydrogenase complex; PDHC; thiamine; glycolysis; glucose; insulin; lipopolysaccharides; LPS; oxidative phosphorylation; OXPHOS; pyruvate dehydrogenase kinase; PDK; lactate

Introduction

Sepsis is responsible for 20% of global deaths and ranks as the costliest condition in United States hospitals, averaging approximately \$46,000 per patient. Despite this, treatment options remain largely supportive, with hospitalised patient mortality at around 27% and intensive care patient mortality reaching 42%. It is claimed that sepsis was responsible for most deaths during the COVID-19 pandemic [1]. Notably, mortality rates in the United States remained static between 1999 and 2022 [2]. While early recognition is thought to enhance survival, the evidence underpinning Early Warning Scores (EWS) is limited [3].

Health costs do not end with the acute phase of sepsis. Prior sepsis is the most common reason for 30-day unplanned rehospitalization with healthcare costs exceeding diseases such as acute myocardial infarction, chronic obstructive pulmonary disease, heart failure and pneumonia [1]. 31.5% Of survivors rely on nursing care for 3 years after discharge and the healthcare burden of these global survivors is \$ billions per year [4].

Is Sepsis a Dysregulated Response to Infection?

The current understanding of sepsis is that it is life threatening disorder caused by a dysregulated host response to infection associated with organ dysfunction.

However, sepsis is not a dysregulated response but a highly regulated response and defence against invading microorganisms. It represents millions of years of evolution honing the body's defences against invading organisms.

Prior to the advent of antibiotics this was the organism's only defence and it was relatively successful. For example, survival from uncomplicated pneumococcal pneumonia was 70% [5]. The spleen also illustrates the effectiveness of these immune defences because of its role in leukocyte production, antibody production, phagocytic filtering out of bacteria and opsonizing bacteria. Thus, splenectomy significantly increases the risk of death from infections, and the mortality rate can be as high as 70% and occur under 24 hours in overwhelming post-splenectomy infections [6].

This process becomes "dysregulated" or "breaks down" particularly under two circumstances – overwhelming infection and deficiencies of thiamine and/or intracellular glucose to provide ongoing fuel for the immune system and/or OXPHOS. Glucose inadequacy is also a prominent cause of death in premature infants because of the heightened risk of hypoglycaemia.

Sepsis as a Physiological Response to Infection

The hypermetabolic phase of sepsis represents this defensive process. Leucocyte numbers surge and migrate to sites of infection and tissue injury. Immune activation during sepsis is an energy intensive process and raises metabolic rates by 37–55%. Glucose consumption increases to fuel this increased demand and glucose production increases to meet this. Insulin resistance reduces glucose uptake by less essential organs, while the liver boosts glucose output and the kidneys increase glucose reabsorption. Adipose tissue releases more free fatty acids and glycerol, which are used as alternative fuels or substrates for hepatic glucose production. Skeletal muscle is catabolised to supply amino acids for gluconeogenesis [7,8]. In severe infections like malaria, hepatic glucose output can double from 200 to 400 g/day [9,10].

Children, who have lower glycogen reserves than adults, are especially vulnerable to severe hypoglycaemia because of this diversion of available glucose, which can increase mortality four to sixfold compared to children without hypoglycaemia [9,10].

Anaerobic glycolysis becomes the preferred ATP-producing pathway, particularly for immune cells, because it is capable of generating ATP 100 times faster than OXPHOS and functions effectively under anaerobic or ischaemic conditions characteristic of infected or damaged tissues. Other organs, including the kidneys and heart, also partially switch to glycolysis for ATP production. Unlike exercise-induced rises in lactate, which do not suppress OXPHOS or increase morbidity [11], sepsis-related lactate elevations are linked to high mortality [12].

In healthy organisms, 95% of cellular ATP is produced via mitochondrial OXPHOS, amounting to 100–150 moles or 25–40 kg per day [8].

Experimental studies, such as those with Holstein cows, illuminate this sequence of metabolic events. The administration of lipopolysaccharide (LPS)—a component of gram-negative bacterial membranes—caused serum glucose levels to spike from 60 mg/dL (4 mmol/l) to 155 mg/dL (9 mmol/l) within 30 minutes, indicating acute insulin resistance. Subsequently, glucose levels dropped to a deficiency at 30 mg/dL (2 mmol/l) due to increased immune demand, necessitating glucose infusion to maintain euglycemia. This diversion of glucose to the immune system, away from tissues like the mammary glands—which exhibited an 80% reduction in milk production—demonstrates the body's prioritisation of immune function during perceived threats, even without live microbes [13].

Imaging studies using radiolabelled glucose and positron emission tomography in Dutch dwarf rabbits also illuminate this process and have shown a marked reduction in glucose uptake by most organs after LPS administration because of the diversion of glucose to the immune system, with

increased renal glucose uptake also to support the immune system. This diversion leads to hypothermia, as limited glucose availability curtails less critical functions like thermogenesis [14].

Another critical change during sepsis is the inhibition of the mitochondrial pyruvate dehydrogenase complex (PDHC), driven by increased activity of PDK enzymes. This suppression of mitochondrial ATP production is corroborated by proteome analyses, which demonstrate elevated PDK and reduced PDHC levels during sepsis [7,8].

The Hypometabolic Phase of Sepsis

The hypometabolic phase of sepsis represents the “dysregulation” or “breaking down” of the sepsis process. While glycolysis can rapidly supply ATP, it is insufficient for the ongoing energy needs of the entire organism. Its role is primarily to meet the urgent ATP demands of immune cells operating in low-oxygen or ischaemic environments [7,8]. This limitation is evident in sepsis-induced cardiac dysfunction, as the heart depends on continual ATP supply and mitochondrial dysfunction is central to septic cardiomyopathy, an organ with the highest mitochondrial density [15].

Non-surviving septic patients exhibit elevated respiratory capacity but reduced mitochondrial respiration associated with ATP synthesis, while survivors show increased mitochondrial activity during recovery [7]. There is a direct correlation between body temperature at emergency department admission and mortality: patients with temperatures below 35°C have a 48% 30-day mortality rate, compared to 11% for those above 41°C [16]. The generation of fever requires uncoupled mitochondrial respiration [17], and inhibition of mitochondrial function suppresses fever [18].

The hypometabolic phase is characterised by decreased oxygen consumption (VO₂) and basal metabolic rate, despite high respiratory capacity and poor response to increased systemic oxygen. Multi-organ dysfunction syndrome (MODS) is a prominent feature, marked by minimal cell death, reduced substrate consumption, and normal or elevated tissue oxygen levels. MODS may represent an adaptive strategy to minimise energy requirements, similar to hibernation [8,19]. Even sepsis-induced cardiac dysfunction may reflect functional, adaptive changes to reduce oxygen and ATP consumption [20]. During recovery, hospital survivors show a 50–60% increase in systemic VO₂ and resting metabolic rate, consistent with renewed mitochondrial ATP production [18].

Hyperglycaemia

Glucose availability is a key factor influencing both the risk of developing sepsis and subsequent mortality. Neonates, particularly those born preterm, are at increased risk due to limited glycogen and fat stores, low gluconeogenic enzyme expression, and high glucose requirements for their larger brain. Unable to adequately respond to hypoglycaemia, up to 60% require supplementary glucose to prevent morbidity and long-term complications [21], and they are more susceptible to sepsis and sepsis-related death [22,23].

Children aged 5–14 exhibit significantly lower sepsis-related mortality than adults, even when infection rates are similar. This phenomenon, observed in events like the 1918 flu pandemic and other infectious diseases, is likely linked to higher glucose availability [24]. Children have three times the normalised glucose production of adults [25,26] and lower insulin resistance, reflecting greater glucose surplus [27,28].

Data also indicate that patients with hyperthermia are more likely to survive sepsis than those with hypothermia [16]. Since glucose is the primary fuel for the activated immune system, those able to maintain elevated body temperatures during infection have surplus glucose beyond immune needs, whereas those with marginal glucose reserves may lack sufficient fuel for thermogenesis, resulting in hypothermia. Mechanically ventilated septic patients warmed with forced-air blankets for 48 hours experienced a 25% reduction in 28-day mortality [29].

Hyperinsulinemia

Insulin availability similarly impacts sepsis risk and outcomes. The heart, with the highest ATP consumption of any organ, is particularly sensitive to ATP availability. Patients with chronic heart failure often exhibit elevated insulin resistance, and low insulin levels are associated with increased mortality [30]. Studies in animal models have shown that insulin administration improves cardiac output, oxygen delivery, and vascular resistance following LPS challenge [31].

Mitochondrial protein synthesis is vital for cellular function and increases only when essential amino acids are infused alongside high insulin concentrations [32]. Glucose is a major myocardial fuel, especially under low-oxygen or ischaemic conditions, and insulin orchestrates glucose uptake, glycolysis, and mitochondrial oxidation, directly enhancing ATP production [33].

Acute kidney injury (AKI) affects over 40% of septic patients, with mitochondrial dysfunction contributing through excessive reactive oxygen species (ROS), ATP depletion, and membrane potential disruption. Insulin therapy mitigates mitochondrial damage, reverses ATP depletion, reduces oxidant production, improves antioxidant levels, and suppresses renal mitophagy [34].

Elevated insulin concentrations in septic patients increase glucose uptake and oxidation [35]. In animal studies, high-dose insulin (HDI) improved survival rates during septic shock [36]. In mice, LPS administration raised insulin levels without altering blood glucose, but blocking insulin secretion resulted in severe hyperglycaemia and increased mortality. Non-survivors had significantly lower insulin levels compared to survivors [37]. In paediatric burn patients, intensive insulin therapy decreased infection and sepsis incidence, alleviated insulin resistance, reduced catabolism, and lowered mortality [38]. Insulin also enhanced survival and reduced positive blood cultures in rodent models of burn wound infection [39].

Glucose Plus Insulin

Both increased glucose and insulin availability individually improve sepsis survival, and their combination has a compounding effect. In vitro, cardiomyocytes exposed to simulated ischemia showed up to 75% greater ATP production and 40% less lactate when treated with glucose and insulin, reducing cellular injury [40]. Septic rats treated to maintain blood glucose between 8–10 mmol/L displayed superior glucose utilisation and increased expression of glucose transporter GLUT4 [41].

Much morbidity and mortality from septic shock stem from refractory hypotension and cardiovascular collapse; thus, counteracting these effects may improve outcomes. Administration of glucose-insulin-potassium (GIK) to patients with severe sepsis and septic shock improved mean arterial pressure and reduced heart rate in those with hypodynamic myocardial depression. The total insulin dose correlated with haemodynamic improvement [42].

The Pyruvate Dehydrogenase Complex

Restoring mitochondrial ATP production during sepsis requires overcoming two barriers: severe insulin resistance and suppression of PDHC. High-dose insulin can address insulin resistance, increasing intracellular glucose. Suppression of PDHC, which inhibits pyruvate transfer into mitochondria, is mediated by PDK enzymes. Glycolysis produces ATP by converting glucose to pyruvate and lactate in the cytoplasm (yielding two ATP units). Under aerobic conditions, pyruvate enters mitochondria and is oxidised to acetyl-CoA via PDHC, producing 36 ATP units. PDHC is suppressed in sepsis, but PDK activity can be inhibited by agents such as dichloroacetate (DCA), thiamine, amrinone, TNF-binding protein, and ciprofloxacin, each enhancing mitochondrial pyruvate uptake and ATP generation [43].

PDHC activity changes are not limited to immune cells; sepsis-induced cardiomyopathy—a major cause of death—correlates with increased PDK4 levels and PDHC inhibition [44]. PDK inhibitors also rebalance metabolic and transcriptional responses in liver cells during the low-energy, anti-inflammatory phase of sepsis [45].

Thiamine

Thiamine, a vitamin and PDK inhibitor, is linked to improved clinical outcomes in sepsis. A review of over 11,500 Sepsis-3 patients found that intravenous thiamine reduced 28-day mortality and the risk of myocardial infarction [46]. However, clinical trials of thiamine supplementation have yielded mixed results, potentially due to differences in dosage, administration route, timing, presence or absence of deficiency, duration, sample size, septic phenotype, and medication combinations. Some trials have shown positive effects, particularly in patients with severe pneumonia [47], while others have found no benefit in septic shock [48].

Treatment with a Combination of Thiamine and Glucose

A recent study evaluated the impact of thiamine plus glucose treatment for sepsis.

A cecal ligation and puncture (CLP) model of mouse sepsis evaluated antibiotics, thiamine and glucose [12]. All four groups of animals were administered antibiotics (Ceftriaxone and metronidazole administered intraperitoneally). One group was also administered glucose. Another group was also administered thiamine. A third group was also administered glucose and thiamine. The fourth group was administered the antibiotics only.

Survival of the thiamine plus glucose plus antibiotic group at 100 hours was 90% whereas survival of the antibiotic only group at 100 hours was 10%. While this was a short-term outcome it is the first validation of the thrust of a paper published in 2023 by the author proposing thiamine plus glucose treatment for sepsis [49].

The addition of insulin will further enhance survival particularly longer-term survival because insulin counteracts insulin resistance and thereby enhances glucose transfer into the intracellular cytoplasm. An important element for inhibiting the sepsis process is intracellular glucose availability because this is a key precursor to mitochondrial ATP production.

Conclusion

High-dose insulin combined with mild hyperglycaemia and PDK inhibitors such as intravenous thiamine act on distinct enzymatic pathways, overcoming barriers to mitochondrial ATP production. This combination, if administered during a critical window in the sepsis process, may significantly enhance survival from sepsis.

References

1. Hancock R, An A, dos Santos C, Lee A. Deciphering sepsis; transforming diagnosis and treatment through systems immunology. *Front Sci* 2025;2:1469417. doi: 10.3389/fsci.2024.1469417.
2. Morrissey R, Lee J, Baral J, Tauseef A, Sood A, Mirza M, Jabbar A, Demographic and regional trends of sepsis mortality in the United States, 1999-2022. *BMC Infect Dis* 2025; 25:504 doi.org/10.1186/s12879-025-10921-7.
3. Verma A. Toward the Rigorous Evaluation of Early Warning Scores. *JAMA Network Open*. 2024;7(10): e2428966.doi.10:1001/jamanetworkopen.2024.38966.
4. Cheng L, Cao Y, Liu S, Lv L, Zhang J, Bao J, et al. Unveiling the research advances of sepsis: pathogenesis, precise intervention and clinical perspective. *Int J Surg* 2025;111:6260-89.
5. Shlaes DM, Bradford PA. Antibiotics – From There to Where? How the antibiotic miracle is threatened by resistance and a broken market and what we can do about it. *Pathogens and Immunology* 2018;13(13):19-43. doi: 10.20411/pai.v3i1.231.
6. Siedlecki E, Rosinski M, Paczek L. Consequences of splenectomy: immunological, hematological, and organ-specific. *Curr Probl Surg* 2025;73:101931. Doi.org/10.1016.
7. Preau S, Vodovar D, Jung B, Lancel S, Zafrani I, Flatres A, et al. Energetic dysfunction in sepsis: a narrative review. *Ann Intensive Care* 2021;11(1):104.

8. Liu J, Zhou G, Wang X, Liu D. Metabolic reprogramming consequences of sepsis: adaptations and contradictions. *Cell Mol Life Sci* 2022; 79:456.
9. Zijlmans W, van van Kempen A, Serlie M, Sauerwein H. Glucose metabolism in children: influence of age, fasting, and infectious diseases. *Metabolism* 2009;58(9):1356-65.
10. Zijlmans W, van van Kempen A, Serlie M, Kager P, Sauerwein H. Adaptation of glucose metabolism to fasting in young children with infectious diseases: a perspective. *J Pediatr Endocrinol Metab* 2013; 27:5-13.
11. Mandadzhiev N. The contemporary role of lactate in exercise physiology and exercise prescription – a review of the literature. *Folia Medica (Plovdiv)* 2025 Feb 24; 67(1). doi 10.3897/folmed.67. e144693.
12. Nuytens L, Heyerick M, Heremans G, Moens E, Roes M, Van Dender C, et al. Unravelling mitochondrial pyruvate dysfunction to mitigate hyperlactatemia and lethality in sepsis. *Cell Rep.* 2025 Aug 26; 44(8):116032. doi:10.1016/j.celrep.2025.116032.
13. Kvidera S, Horst E, Abuajamieh M, Mayorga E, Sanz-Fernandez M, Baumgard L. Glucose requirements of an activated immune system in Holstein cows. *J Dairy Sci* 2017; 100:2360-74.
14. Luna-Reyes I, Perez-Hernandez E, Delgado-Coello B, Avila-Rodriguez M, Mas-Oliva J. Peptide VSAK maintains tissue glucose uptake and attenuates pro-inflammatory responses caused by LPS in an experimental model of the systemic inflammatory response syndrome: a PET study. *Sci Rep* 2021; 11:14752.
15. Jarczак D, Kluge S, Nierhaus A. Sepsis-Pathophysiology and Therapeutic Concepts. *Front Med (Lausanne)*. 2021 May 14; 8:628302. doi:10.3389/fmed.2021.628302.
16. Inghammar M, Sundén-Cullberg J. Prognostic significance of body temperature in the emergency department vs ICU in Patients with severe sepsis or septic shock: A nationwide cohort study. *PLoS ONE* 2020;15(12): e0243990.
17. Greco E, Arulkumaran N, Dyson A, Singer M. 0035. Mitochondrial uncoupling contributes to fever in sepsis. *Intensive Care Medicine Experimental*. 2014 Sep;2(Suppl 1). PMID: PMC 479280.
18. Guimaraes N, Alves D, Vilela W, de-Souza-Ferreira E, Gomes B, Ott D, et al. Mitochondrial pyruvate carrier as a key regulator of fever and neuroinflammation. *Brain Behav Immun* 2021; 92:90-101.
19. Wasyluk W, Zwolak A. Metabolic Alterations in Sepsis. *J Clin Med* 2021; 10:2412.
20. Mokhtari B, Yavari R, Badalzadeh R, Mahmoodpoor A. An Overview on Mitochondrial-Based Therapies in Sepsis-Related Myocardial Dysfunction: Mitochondrial Transplantation as a Promising Approach. *Can J Infect Dis Med Microbiol* 2022; 2022:3277274.
21. Sharma A, Davis A, Shekhawat P. Hypoglycemia in the preterm neonate: etiopathogenesis, diagnosis, management and long-term outcomes. *Transl Pediatr* 2017;6(4):335-48.
22. Watson R, Carcillo J, Linde-Zwirble W, Clermont G, Lidicker J, Angus D. The Epidemiology of Severe Sepsis in Children in the United States. *Am J Respir Crit Care Med* 2003; 167:695-701.
23. Li L, Sunderland N, Rathnayake K, Westbrook J (2021). Sepsis epidemiology in Australian Public Hospitals, a nationwide longitudinal study (2013-2018). *Infection, Disease & Health*, ISSN:2468-0451, Vol:26, Page:59.
24. Joachim R, Altschuler G, Hutchinson J, Wong H, Hide W, Kobzik L. The relative resistance of children to sepsis mortality: from pathways to drug candidates. *Mol Syst Biol* 2018;14:e7998.
25. Bier D, Leake R, Haymond M, Arnold K, Gruenke L, Sperling M, Kipnis D. Measurement of “true” glucose production rates in infancy and childhood with 6,6-dideuteroglucose. *Diabetes* 1977;26(11):1016-23.
26. Kuzawa C, Chugani H, Grossman L, Lipovich L, Muzik O, Hof P, et al. Metabolic costs and evolutionary implications of human brain development. *PNAS* 2014;111(36):13011.
27. Jeffery A, Metcalf B, Hosking J, Streeter A, Voss L, Wilkin T. Age Before Stage: Insulin Resistance Rises Before the Onset of Puberty. *Diabetes Care* 2012; 35:536-41.
28. Amiel S, Sherwin R, Simonson D, Lauritano A, Tamborlane W. Impaired Insulin Action in Puberty. *N Eng J Med* 1986; 315:215-9.
29. Drewry A, Mohr N, Ablordeppey E, Dalton C, Doctor R, Fuller B, Kollef M, Hotchkiss R. Therapeutic Hyperthermia Is Associated With Improved Survival in Afebrile Critically Ill Patients With Sepsis: A Pilot Randomized Trial. *Crit Care Med* 2022;50(6):924-34.
30. Nogi M, Kawakami R, Ishihara S, Kirai K, Nakada Y, Nakagawa H, et al. Low insulin Is an Independent Predictor of All-Cause and Cardiovascular Death in acute Decompensated Heart Failure Patients Without Diabetes Mellitus. *J Am Heart Assoc* 2020;9: e015393.

31. Levenbrown Y, Penfil S, Rodriguez E, Zhu Y, Hossain J, Bhat M, et al. Use of Insulin to Decrease Septic Shock-Induced Myocardial Depression in a Porcine Model. *Inflammation* 2013; 36:1494-1502.
32. Robinson M, Soop M, Sohn T, Morse D, Schimke J, Klaus K, Nair K. High Insulin Combined With Essential Amino Acids Stimulates Skeletal Muscle Mitochondrial Protein Synthesis While Decreasing Insulin Sensitivity in Healthy Humans. *J Clin Endocrinol Metab* 2014;99(12): E2574-E2583.
33. Karwi Q, Wagg C, Altamimi T, Uddin G, Ho K, Darwesh A, et al. Insulin directly stimulates mitochondrial glucose oxidation in the heart. *Cardiovasc Diabetol* 2020; 19:207.
34. Chen GD, Zhang JL, Chen YT, Zhang JX, Wang T, Zeng QY. Insulin alleviates mitochondrial oxidative stress involving upregulation of superoxide dismutase 2 and uncoupling protein 2 in septic acute kidney injury. *Exp Ther Med* 2018; 15:3967-75.
35. Rusavy Z, Sramek V, Lacigova S, Novak I, Tesinsky P, Macdonald I. Influence of insulin on glucose metabolism and energy expenditure in septic patients. *Crit Care* 2004;8: R213-R220.
36. Holger J, Dries D, Barringer K, Peake B, Flottesmesch T, Marini J. Cardiovascular and Metabolic Effects of High-dose Insulin in a Porcine Septic Shock Model. *Acad Emerg Med* 2010;17(4):429-35.
37. Woodske M, Yokoe T, Zou B, Romano L, Rosa T, Garcia-Ocana A, et al. Hyperinsulinemia predicts survival in a hyperglycemic mouse model of critical illness. *Crit Care Med* 2009;37(9):2596-603.
38. Jeschke M, Kulp G, Kraft R, Finnerty C, Micak R, Lee J, Herndon D. Intensive Insulin Therapy in Severely burned Pediatric Patients. *Am J Respir Crit Care Med* 2010; 182:351-9.
39. Gauglitz G, Toliver-Kinsky T, Williams F, Song J, Cui W, Herndon D, Jeschke M. Insulin increases resistance to burn wound infection-associated sepsis. *Crit Care Med* 2010; 38(1): doi:10.1097/CCM.0b013e3181b43236.
40. Rao V, Merante F, Weisel R, Shirai T, Ikonomidis J, Cohen G, et al. Insulin stimulates pyruvate dehydrogenase and protect human ventricular cardiomyocytes from simulated ischemia. *J Thorac Cardiovasc Surg* 1998; 116:485-94.
41. Lu G, Cui P, Cheng Y, Lu Z, Zhang L, Kissoon N. Insulin Control of Blood Glucose and GLUT4 Expression in the Skeletal Muscle of Septic Rats. *West Ind Med J* 2015;64(2):62-70.
42. Kim W, Baek M, Kim Y, Seo J, Huh J, Lim C, et al. Glucose-insulin-potassium correlates with hemodynamic improvement in patients with septic myocardial dysfunction. *J Thorac Dis* 2016;8(12):3648-57.
43. Zeng Z, Huang Q, Mao L, Wu J, An S, Chen Z, Zhang W. The Pyruvate Dehydrogenase Complex in Sepsis: Metabolic Regulation and Targeted Therapy. *Front Nutr* 2021; 8:783164.
44. Shimada B, Boyman L, Huang W, Zhu J, Yang Y, Chen F, et al. Pyruvate-Driven Oxidative Phosphorylation is Downregulated in Sepsis-Induced Cardiomyopathy: A Study of Mitochondrial Proteome. *Shock* 2022;57(4):553-64.
45. Mainali R, Zabalawi M, Long D, Buechler N, Quillen E, Key C, et al. Dichloroacetate reverses sepsis-induced hepatic metabolic dysfunction. *Elife* 2021;10: e64611.
46. Zhang L, Zhang F, Li S, Xu F, Zheng X, Huang T, et al. Thiamine supplementation may be associated with improved prognosis in patients from sepsis, *Br J Nutr* 2022 Oct 19;1-10. doi: 10.1017/S0007114522003373.
47. Kim W-Y, Jo E-J, Eom J-S, Mok J, Kim M-H, Kim K, et al. Combined vitamin C, hydrocortisone, and thiamine therapy for patients with severe pneumonia who were admitted to the intensive care unit: Propensity score-based analysis of a before-after cohort study. *J Crit Care* 2018; 47:211-8.
48. Hwang S, Ryoo S, Park J, Jo Y, Jang D-H, Suh G, et al. Combination therapy of vitamin C and thiamine for septic shock: a multi-centre, double-blind randomized, controlled study. *Intensive Care Med* 2020; 46:2015-25.
49. Bradley P. Thiamine and high dose insulin treatment for sepsis. *Cent Asian J Med Hypotheses Ethics* 2023;4(2):77-88.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.